First National Advisers LLC Has $7.90 Million Stake in Eli Lilly and Company $LLY

First National Advisers LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,129 shares of the company’s stock after purchasing an additional 158 shares during the quarter. Eli Lilly and Company accounts for about 1.2% of First National Advisers LLC’s portfolio, making the stock its 12th biggest position. First National Advisers LLC’s holdings in Eli Lilly and Company were worth $7,896,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of LLY. Lazard Freres Gestion S.A.S. raised its holdings in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares during the period. Precedent Wealth Partners LLC lifted its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the period. Family CFO Inc purchased a new stake in Eli Lilly and Company in the second quarter worth $54,000. Finally, Duquesne Family Office LLC raised its stake in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LLY shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. CICC Research increased their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Cantor Fitzgerald lifted their price objective on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Price Performance

LLY stock opened at $1,074.94 on Friday. The firm has a 50 day moving average of $889.37 and a 200-day moving average of $799.23. The firm has a market capitalization of $1.02 trillion, a P/E ratio of 70.26, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.